Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin II-induced heart failure in vivo.
about
Therapeutic potential of PDE modulation in treating heart diseaseClinical Phenotypes in Heart Failure With Preserved Ejection FractionPriming the proteasome by protein kinase G: a novel cardioprotective mechanism of sildenafilOlmesartan prevents cardiac rupture in mice with myocardial infarction by modulating growth differentiation factor 15 and p53In Vivo Protective Effects of Diosgenin against Doxorubicin-Induced Cardiotoxicity.The NO/ONOO-cycle as the central cause of heart failure.Pre-clinical diastolic dysfunctionRole of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target.Investigational drugs targeting cardiac fibrosis.New insights in (inter)cellular mechanisms by heart failure with preserved ejection fraction.Effects of PDE type 5 inhibitors on left ventricular diastolic dysfunction in resistant hypertension.Everything you ever wanted to know about phosphodiesterase 5 inhibitors and the heart (but never dared ask): How do they work?Challenges and opportunities in treating inflammation associated with pulmonary hypertension.Tadalafil prevents acute heart failure with reduced ejection fraction in mice.Human Endomyocardial Biopsy Specimen-Derived Stromal Cells Modulate Angiotensin II-Induced Cardiac Remodeling.Murine Models of Heart Failure with Preserved Ejection Fraction: a "Fishing Expedition".Role of Toll-like receptors and interferon regulatory factors in different experimental heart failure models of diverse etiology: IRF7 as novel cardiovascular stress-inducible factor.Cardiac fibroblasts support cardiac inflammation in heart failure.
P2860
Q27005761-E7C0566D-0282-4C7B-A6BE-E1BF1A2AD353Q28073079-6F0948DF-A38A-4F28-BEEF-FBF980A4A8A9Q28084015-1FF03E41-82C5-47FE-B11E-9246347F1298Q34025188-00EF5141-EA42-481F-A182-0A5026F6DEE9Q35809052-84A2E679-C69E-4213-899A-39ABCA54A4A1Q37375441-7C92802D-F35D-486C-A3FA-C0DBA8E633FDQ37603551-DE56B5EF-4C80-4E03-9215-6BC63DE1B0BFQ38134311-614CFB0C-AB08-4749-BC30-37B29D489C81Q38161896-479615EB-372A-4310-8AA9-31F39283229DQ38246170-326BB342-604A-4BB4-99D2-DC9B380DB451Q38263477-44BF2FA4-5C5C-4121-9B22-E2E3B0E2B942Q38542767-4CEC5164-F710-437D-A249-2DF0334929B9Q38812727-F5825A93-C0E2-4178-A5D2-F563DE44720AQ45004611-688D157C-8757-405E-A430-B013DB7F3571Q46510689-B3EE840D-856C-4DE9-8360-D17E0F2A0B06Q49203906-8F74FCAE-A954-4D02-80BB-D0F310FD1DF4Q52655959-EA2347C3-483C-4AAE-944A-582EEFBA8DF0Q54196284-BEDF9306-E4C1-4D0E-8247-502E98FFB1D3
P2860
Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin II-induced heart failure in vivo.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Selective PDE5A inhibition wit ...... induced heart failure in vivo.
@en
Selective PDE5A inhibition wit ...... induced heart failure in vivo.
@nl
type
label
Selective PDE5A inhibition wit ...... induced heart failure in vivo.
@en
Selective PDE5A inhibition wit ...... induced heart failure in vivo.
@nl
prefLabel
Selective PDE5A inhibition wit ...... induced heart failure in vivo.
@en
Selective PDE5A inhibition wit ...... induced heart failure in vivo.
@nl
P2093
P2860
P1476
Selective PDE5A inhibition wit ...... -induced heart failure in vivo
@en
P2093
Carsten Tschöpe
Dirk Westermann
Heinz-Peter Schultheiss
Kostantinos Savvatis
Peter Moritz Becher
Sebastian Hoffmann
P2860
P2888
P356
10.1007/S00395-012-0308-Y
P577
2012-11-02T00:00:00Z